Traders should monitor upcoming milestones, including the potential initiation of a registrational Phase 3 trial for givastomig in Q4 2026 and the initiation of a Phase 2b study for VIS-101 in H2 2026. The company's strong cash position reduces near-term financing risk, making clinical data readouts the primary catalysts.
Price Chart
Executive Summary
NovaBridge Biosciences reported strong clinical progress in 2025, highlighted by robust data for its lead candidates givastomig and VIS-101, which demonstrated potential for accelerated approval pathways. The company successfully transitioned to a global biotech platform, secured $210.8 million in cash, and is well-positioned to advance its pipeline through 2028. This progress follows a strategic reprioritization and the divestiture of its Greater China assets.
Key Facts
- Reported positive Phase 1b data for givastomig in gastric cancer, showing a 75% objective response rate and 16.9-month median progression-free survival.
- Announced FDA alignment on givastomig's potential eligibility for an accelerated approval pathway.
- Reported positive Phase 2a data for VIS-101 in wet-AMD, showing rapid, robust, and durable responses.
- Company has $210.8 million in cash, sufficient to fund operations into Q4 2028.
- Successfully transitioned to a global biotech platform with a new name and leadership team.
- Completed the divestiture of its Greater China assets and business operations in April 2024.
Financial Impact
The company reported a net loss of $88.3 million for 2025, but its $210.8 million cash position provides strong financial stability.
Risk Factors
- The company has a limited operating history and has incurred significant net losses.
- It depends heavily on the success of its drug candidates, all of which are in preclinical or clinical development.
- The company may need to obtain additional financing in the future.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 16 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 20-F Filing (Primary) | 0001778016-26-000002 |
| Document: nbp-ex11_2.htm | 0001778016-26-000002 |
| Document: nbp-ex4_34.htm | 0001778016-26-000002 |
| Document: nbp-ex4_18.htm | 0001778016-26-000002 |
| Document: nbp-ex15_1.htm | 0001778016-26-000002 |
| Document: nbp-ex15_4.htm | 0001778016-26-000002 |
| Document: nbp-ex12_1.htm | 0001778016-26-000002 |
| Document: nbp-ex12_2.htm | 0001778016-26-000002 |
| Document: nbp-ex8_1.htm | 0001778016-26-000002 |
| Document: nbp-ex15_2.htm | 0001778016-26-000002 |
| Document: nbp-ex13_1.htm | 0001778016-26-000002 |
| Document: nbp-ex13_2.htm | 0001778016-26-000002 |
| Document: nbp-ex15_3.htm | 0001778016-26-000002 |
| Document: 0001778016-26-000002-index-headers.html | 0001778016-26-000002 |
| Document: 0001778016-26-000002-index.html | 0001778016-26-000002 |
| Document: 0001778016-26-000002.txt | 0001778016-26-000002 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 1d ago | 6-K | $1.22 | awaiting T+5 | — | $1.25 (+3.29%) |
Oct 25, 2026 2d ago | Press Release | $1.22 | awaiting T+5 | — | $1.25 (+3.29%) |
Oct 23, 2026 4d ago | 6-K | $1.37 | awaiting T+5 | — | $1.25 (−8.39%) |
Oct 13, 2026 14d ago | 6-K | $1.29 $1.43 | ▲ +10.47% | ▲ +11.62% | $1.25 (−2.71%) |
Sep 8, 2026 7w ago | 6-K | $1.78 $1.61 | ▼ −9.55% | ▼ −8.89% | $1.25 (−29.49%) |
Sep 8, 2026 7w ago | 6-K | $1.78 $1.61 | ▼ −9.55% | ▼ −8.89% | $1.25 (−29.49%) |
Aug 20, 2026 9w ago | 6-K | $1.91 $1.89 | ▲ +1.05% | ▲ +2.16% | $1.25 (+34.29%) |
Aug 20, 2026 9w ago | 6-K | $1.91 $1.89 | ▼ −1.05% | ▼ −2.16% | $1.25 (−34.29%) |
Aug 20, 2026 9w ago | Press Release | $1.91 $1.89 | ▲ +1.05% | ▲ +2.16% | $1.25 (+34.29%) |
Jul 24, 2026 13w ago | 6-K | $1.78 $1.60 | ▼ −10.11% | ▼ −11.19% | $1.25 (−29.49%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers